Last 48 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
IDEXX Laboratories, Inc.'s quarterly P/E stands at 40.7x, up 14.8% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 26.6% YoY to 31.9x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 42.97 | 40.72 | 54.91 | 46.98 | 36.94 | 35.47 | 39.45 | 45.11 | 49.92 | 48.04 | 59.81 | 43.21 | 47.03 |
| — | +14.8% | +39.2% | +4.1% | -26.0% | -26.2% | -34.0% | +4.4% | +6.2% | -2.0% | +20.2% | +14.1% | -16.3% | |
| P/S Ratio | 10.37 | 9.93 | 12.51 | 11.66 | 9.79 | 8.61 | 8.94 | 10.75 | 10.12 | 11.75 | 12.92 | 10.03 | 11.17 |
| — | +15.3% | +40.0% | +8.4% | -3.3% | -26.7% | -30.8% | +7.2% | -9.4% | +0.8% | +25.2% | +23.2% | +29.2% | |
| P/B Ratio | 28.25 | 29.13 | 34.00 | 33.01 | 29.78 | 23.76 | 21.39 | 25.93 | 25.71 | 28.89 | 31.38 | 28.31 | 38.56 |
| — | +22.6% | +58.9% | +27.3% | +15.8% | -17.8% | -31.8% | -8.4% | -33.3% | -42.1% | -44.1% | -50.8% | -40.8% | |
| P/FCF | 42.38 | — | 42.30 | 34.71 | 71.62 | 41.36 | 38.30 | 54.64 | 47.24 | 67.33 | 53.60 | 38.52 | 61.01 |
| — | — | +10.5% | -36.5% | +51.6% | -38.6% | -28.6% | +41.8% | -22.6% | -7.4% | -15.9% | -14.9% | -70.7% | |
| EV / EBITDA | 31.05 | 31.86 | 39.14 | 33.49 | 27.22 | 25.17 | 29.47 | 31.54 | 34.88 | 34.97 | 42.90 | 30.84 | 33.33 |
| — | +26.6% | +32.8% | +6.2% | -22.0% | -28.0% | -31.3% | +2.3% | +4.6% | -0.0% | +23.2% | +17.1% | -11.3% | |
| EV / EBIT | 33.49 | 31.86 | 43.68 | 36.89 | 29.78 | 27.77 | 32.87 | 34.78 | 38.64 | 37.91 | 47.40 | 33.93 | 36.43 |
| — | +14.7% | +32.9% | +6.1% | -22.9% | -26.7% | -30.7% | +2.5% | +6.1% | -1.4% | +20.9% | +15.5% | -16.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
IDEXX Laboratories, Inc.'s operating margin was 31.8% in Q1 2026, up 2.8 pp QoQ and up 0.1 pp YoY.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.8% | 63.4% | 60.3% | 61.8% | 62.6% | 62.4% | 59.8% | 61.1% | 61.9% | 61.5% | 58.4% | 59.9% | 60.7% |
| — | +1.5% | +0.9% | +1.2% | +1.2% | +1.5% | +2.5% | +2.1% | +1.9% | +2.0% | -0.3% | -0.6% | +1.6% | |
| Operating Margin | 31.6% | 31.8% | 28.9% | 32.1% | 33.6% | 31.7% | 27.4% | 31.2% | 26.3% | 31.0% | 27.2% | 30.1% | 31.4% |
| — | +0.3% | +5.5% | +3.1% | +27.9% | +2.2% | +0.8% | +3.6% | -16.2% | -0.4% | -0.5% | +3.4% | +50.8% | |
| Net Margin | 24.6% | 24.4% | 22.8% | 24.8% | 26.5% | 24.3% | 22.7% | 23.9% | 20.3% | 24.4% | 21.6% | 23.2% | 23.8% |
| — | +0.4% | +0.5% | +4.1% | +30.8% | -0.5% | +5.0% | +3.0% | -14.8% | +2.8% | +3.8% | +7.8% | +54.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 66.2% | 17.6% | 15.7% | 18.2% | 20.2% | 15.9% | 13.5% | 14.6% | 12.9% | 15.4% | 14.0% | 17.8% | 23.2% |
| — | +10.5% | +16.5% | +24.9% | +56.7% | +3.4% | -3.8% | -18.0% | -44.3% | -47.7% | -56.0% | -54.2% | -3.7% | |
| ROA | 31.9% | 8.3% | 7.4% | 8.2% | 9.0% | 7.5% | 6.5% | 6.9% | 6.0% | 7.1% | 6.1% | 7.1% | 7.9% |
| — | +10.8% | +13.2% | +18.8% | +49.6% | +4.7% | +6.1% | -3.4% | -23.9% | -7.6% | -4.1% | +3.3% | +55.6% | |
| ROIC | 42.5% | 11.0% | 9.5% | 10.7% | 11.5% | 10.2% | 8.5% | 10.0% | 8.8% | 10.3% | 8.8% | 9.8% | 10.7% |
| — | +7.6% | +11.7% | +6.4% | +30.2% | -0.9% | -2.5% | +2.3% | -17.3% | -1.3% | -0.8% | -0.8% | +41.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
IDEXX Laboratories, Inc.'s Debt/EBITDA ratio is 3.0x — at a moderate level that warrants monitoring.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.67 | 0.69 | 0.67 | 0.71 | 0.85 | 0.73 | 0.62 | 0.62 | 0.68 | 0.68 | 0.72 | 0.88 | 1.05 |
| — | -5.3% | +8.5% | +15.5% | +25.5% | +7.4% | -14.0% | -29.8% | -35.9% | -56.6% | -70.2% | -72.2% | -67.8% | |
| Debt / EBITDA | 0.73 | 2.97 | 3.04 | 2.84 | 3.03 | 3.02 | 3.34 | 2.95 | 3.61 | 3.25 | 3.88 | 3.75 | 3.56 |
| — | -1.6% | -9.0% | -3.7% | -16.1% | -7.0% | -13.9% | -21.2% | +1.4% | -24.0% | -32.6% | -32.0% | -50.7% | |
| Current Ratio | 1.17 | 1.12 | 1.17 | 1.12 | 1.11 | 1.16 | 1.31 | 1.42 | 1.37 | 1.57 | 1.57 | 1.43 | 1.33 |
| — | -3.5% | -11.0% | -20.9% | -18.7% | -26.1% | -16.6% | -0.4% | +2.6% | +45.5% | +76.3% | +60.3% | +49.2% | |
| Quick Ratio | 0.84 | 0.82 | 0.84 | 0.81 | 0.79 | 0.81 | 0.95 | 1.03 | 1.03 | 1.16 | 1.17 | 1.02 | 0.89 |
| — | +1.6% | -12.1% | -21.6% | -23.0% | -30.2% | -18.6% | +1.3% | +16.0% | +63.2% | +97.4% | +72.6% | +45.7% | |
| Interest Coverage | 35.61 | 50.75 | 30.19 | 33.36 | 33.01 | 41.45 | 35.32 | 39.83 | 32.99 | 38.35 | 26.87 | 31.98 | 28.12 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into IDXX consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IDXX stock.
IDEXX Laboratories, Inc.'s current P/E is 43.0x. The average P/E over the last 4 quarters is 44.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
IDEXX Laboratories, Inc.'s current operating margin is 31.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking IDEXX Laboratories, Inc.'s business trajectory between earnings reports.